Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer therapeutics - Carisma Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: anti-cancer therapeutics - Carisma Therapeutics

Alternative Names: Anti-PSMA humabody-deBouganin fusion proteins - Carisma Therapeutics; Armed Antibodies™; NP-1 - Carisma Therapeutics; VB 4011; VB 6901; VB-6008; VB-6011; VB-6050; VB-7756; VB1-008; VB1-050; VBX-008; VBX-011; VBX-050

Latest Information Update: 08 Mar 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Viventia Biotechnologies
  • Developer Carisma Therapeutics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Peptides; Recombinant fusion proteins
  • Mechanism of Action CD44 antigen modulators; Epithelial cell adhesion molecule modulators; Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Mar 2023 Sesen Bio has merged with Carisma Therapeutics to form Carisma Therapeutics
  • 27 Dec 2022 Preclinical development is ongoing in cancer (Sesen Bio pipeline, December 2022)
  • 28 Apr 2020 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top